Related Experiment Video
Updated: May 9, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
Published on: September 25, 2017
Transcriptional network analysis for the regulation of left ventricular hypertrophy and microvascular remodeling
Aida Moreno-Moral1, Massimiliano Mancini, Giulia D'Amati
1Medical Research Council (MRC) Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Imperial Centre for Translational and Experimental Medicine (ICTEM) Building, Du Cane Road, London, W12 0NN, UK.
Insights
Researchers identified gene networks in rat hearts linked to cardiac remodeling, such as left ventricular hypertrophy (LVH) and fibrosis. These findings offer insights into molecular mechanisms of heart disease and may apply to human cardiomyopathies.
Area of Science:
- Cardiovascular Biology
- Molecular Genetics
- Systems Biology
Background:
- Hypertension and cardiomyopathies induce cardiac maladaptive changes, including left ventricular hypertrophy (LVH), fibrosis, and coronary microvascular dysfunction, ultimately leading to heart failure.
- Understanding the molecular basis of LVH-associated cardiac remodeling, independent of blood pressure, is crucial for developing targeted therapies.
Purpose of the Study:
- To identify gene networks and molecular pathways involved in cardiac remodeling and fibrosis in the context of hypertension.
- To investigate gene co-expression patterns associated with quantitative variations in left ventricular hypertrophy (LVH) and microvascular remodeling.
Main Methods:
- Utilized the Spontaneously Hypertensive Rat model, a well-established model for human hypertensive cardiomyopathy.
- Collected histological, histomorphometric, and genome-wide cardiac gene expression data from rat hearts and coronary vasculature.
- Employed gene network approaches to analyze associations between gene co-expression and cardiac traits.
Main Results:
- Generated a comprehensive catalog of cardiac gene co-expression networks significantly associated with variations in LVH, microvascular remodeling, and fibrosis.
- Identified specific gene networks implicated in the structural and molecular changes of the heart and coronary microcirculation.
- Demonstrated significant conservation of identified gene networks between the rat model and human idiopathic and/or ischemic cardiomyopathy patients.
Conclusions:
- Gene co-expression networks play a significant role in cardiac remodeling and fibrosis, independent of elevated blood pressure.
- The identified molecular pathways and gene networks offer potential therapeutic targets for heart failure and cardiomyopathies.
- Findings suggest a conserved molecular basis for cardiac remodeling in rats and humans, highlighting the translational relevance of this study.
Abstract:
Hypertension and cardiomyopathies share maladaptive changes of cardiac morphology, eventually leading to heart failure. These include left ventricular hypertrophy (LVH), myocardial fibrosis, and structural remodeling of coronary microcirculation, which is the morphologic hallmark of coronary microvascular dysfunction. To pinpoint the complex molecular mechanisms and pathways underlying LVH-associated cardiac remodeling independent of blood pressure effects, we employed gene network approaches to the rat heart. We used the Spontaneously Hypertensive Rat model showing many features of human hypertensive cardiomyopathy, for which we collected histological and histomorphometric data of the heart and coronary vasculature, and genome-wide cardiac gene expression. Here, we provide a large catalogue of gene co-expression networks in the heart that are significantly associated with quantitative variation in LVH, microvascular remodeling, and fibrosis-related traits. Many of these networks were significantly conserved to human idiopathic and/or ischemic cardiomyopathy patients, suggesting a potential role for these co-expressed genes in human heart disease.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
